Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

<h4>Objective</h4>Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The objective of this study was to assess factors associated with incident diabetes in rheumatoid arthritis (RA).<h4>Methods</h4>The study population consisted of RA patients...

Full description

Bibliographic Details
Main Authors:	Siri Lillegraven, Jeffrey D Greenberg, George W Reed, Katherine Saunders, Jeffrey R Curtis, Leslie Harrold, Marc C Hochberg, Dimitrios A Pappas, Joel M Kremer, Daniel H Solomon
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0210459

Similar Items

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
by: Laura C. Cappelli, et al.
Published: (2023-10-01)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
by: George W. Reed, et al.
Published: (2017-04-01)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
by: Leslie R. Harrold, et al.
Published: (2018-01-01)

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
by: Shrikant S. Kolan, et al.
Published: (2022-11-01)

Variants of intensification of immunosuppressive therapy of rheumatoid arthritis
by: E A Vasiljeva, et al.
Published: (2007-04-01)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
by: Jeffrey R. Curtis, et al.
Published: (2022-01-01)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
by: Dimitrios A. Pappas, et al.
Published: (2019-06-01)

Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?
by: Yuzhuo Zhang, et al.
Published: (2022-12-01)

Hydroxychloroquine and the risk of respiratory infections among RA patients
by: Joel M Kremer, et al.
Published: (2020-11-01)

Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk
by: Kazuki Yoshida, et al.
Published: (2022-07-01)

Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treat‐to‐Target Rates
by: Betty Hsiao, et al.
Published: (2022-08-01)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
by: Brennan, F, et al.
Published: (1995)

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
by: Anthony S. Padula, et al.
Published: (2022-12-01)

Understanding Heterogeneity in Patients’ Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
by: Jeffrey R Curtis, et al.
Published: (2023-09-01)

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.
by: Kinlen, L
Published: (1985)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
by: Leslie R. Harrold, et al.
Published: (2019-03-01)

Infliximab for the treatment of rheumatoid arthritis.
by: Blumenauer, B, et al.
Published: (2002)

Fusobacterium nucleatum Pleural Empyema in a Patient with Progressive Rheumatoid Arthritis and Immunosuppression
by: Wesley Tang, et al.
Published: (2021-01-01)

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis
by: Tamarah D. de Jong, et al.
Published: (2019-04-01)

Etanercept for the treatment of rheumatoid arthritis.
by: Blumenauer, B, et al.
Published: (2003)

Etanercept for the treatment of rheumatoid arthritis
by: Blumenauer, B, et al.
Published: (2004)

Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?
by: Désirée van der Heijde, et al.
Published: (2024-02-01)

Strongyloides hyperinfection syndrome precipitated by immunosuppressive therapy for rheumatoid arthritis and COVID-19 pneumonia
by: Hasan Hamze, et al.
Published: (2023-10-01)

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
by: Emma C. de Moel, et al.
Published: (2019-01-01)

MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients
by: Fatima Heinicke, et al.
Published: (2021-04-01)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
by: Leslie R. Harrold, et al.
Published: (2023-02-01)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
by: Tore K Kvien, et al.
Published: (2022-01-01)

Effect of different types of immunosuppressive therapy on the parameters of TNF receptor expression in patients with rheumatoid arthritis
by: A. A. Alshevskaya, et al.
Published: (2022-12-01)

EFFICACY OF DIFFERENT IMMUNOSUPPRESSIVE PROTOCOLS WITH CYCLOSPORINE AND METHOTREXATE FOR PATIENTS WITH SYSTEMIC VARIANT OF JUVENILE RHEUMATOID ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2007-01-01)

EFFICACY OF DIFFERENT IMMUNOSUPPRESSIVE PROTOCOLS WITH CYCLOSPORINE AND METHOTREXATE FOR PATIENTS WITH SYSTEMIC VARIANT OF JUVENILE RHEUMATOID ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2007-03-01)

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
by: Philip J. Mease, et al.
Published: (2019-09-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis
by: Shubhasree Banerjee, et al.
Published: (2020-05-01)

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
by: Andrea Rubbert-Roth, et al.
Published: (2023-11-01)

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity
by: Tore K Kvien, et al.
Published: (2024-02-01)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
by: Joel M. Kremer, et al.
Published: (2021-03-01)

Role of interleukin-17 in the pathogenesis of rheumatoid arthritis
by: Jeffrey A Ongkowijaya, et al.
Published: (2018-02-01)

Mechanistic insights into anti-inflammatory and immunosuppressive effects of plant secondary metabolites and their therapeutic potential for rheumatoid arthritis
by: Yuandani, ., et al.
Published: (2024)

A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
by: Leslie R. Harrold, et al.
Published: (2023-09-01)

Modeling of antibody responses to COVID-19 vaccination in patients with rheumatoid arthritis
by: Yun Kyu Kim, et al.
Published: (2024-01-01)